.jetcityimage/iStock Content via Getty Images Morgan Stanley has picked Eli Lilly (NYSE: LLY) as its own leading biopharma pick for 2025 as well as rated an additional 9 labels in the space as overweight. The investment banking company mentioned in a details that it continues to believe “diabesity is actually set to become.